You are here:

micronised progesterone (Utrogestan Vaginal)

Advice

following a full submission:

micronised progesterone (Utrogestan Vaginal®) is accepted for use within NHS Scotland.

Indication under review: in women for supplementation of the luteal phase during Assisted Reproductive Technology (ART) cycles. 

In women receiving luteal support during ART cycles, micronised progesterone 200mg vaginal capsules administered three times daily were non-inferior to another progesterone preparation administered vaginally with respect to ongoing pregnancy rate at the end of the 12th week of gestation.

This advice takes account of the benefits of a Patient Access Scheme (PAS) that improves the cost-effectiveness of micronised progesterone (Utrogestan Vaginal®). This advice is contingent on the continuing availability of the PAS in Scotland or a list price that is equivalent or lower.

Drug Details

Drug Name: micronised progesterone (Utrogestan Vaginal)
SMC Drug ID: 935/13
Manufacturer: Besins Healthcare (UK) Ltd
Indication: In women for supplementation of the luteal phase during Assisted Reproductive Technology (ART) cycles.
BNF Category:
Sub Category: 6.4 Sex Hormones
Submission Type: Full submission
Status: Accepted
Date Advice Published: 8 May 2017

Archived Advice

Non submission 9 December 2013

Back